TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Other Events

Item 8.01

On June 13, 2017, Tonix Pharmaceuticals Holding Corp. (the
Company) presented a poster entitled Phase 2 Multicenter
Double-Blind Placebo-Controlled Trial of TNX-102 SL
(cyclobenzaprine sublingual tablets) in Military-Related
Posttraumatic Stress Disorder (PTSD): Analysis of CAPS-5
Thresholds for Baseline Severity and Week 12 Remission in the
mITT Population and Combat PTSD Subset (the Poster), at the
Pathophysiology of Post-Traumatic Stress Disorder: Rethinking
Drug Targets summit sponsored by the Department of Defense, at
the National Conservation Training Center in West Virginia (the
PTSD Summit).

The foregoing description of the Poster is qualified in its
entirety by reference to the Poster, a copy of which is filed as
Exhibit99.01 to, and is incorporated by reference in, this
report.

On June 15, 2017, the Company issued a press release announcing
the Poster presentation at the PTSD Summit. A copy of the press
release that discusses this matter is filed as Exhibit 99.02 to,
and incorporated by reference in, this report.

The information in this Current Report is being furnished and
shall not be deemed filed for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, except as shall be expressly set forth by specific
reference in any such filing.

* Furnished herewith.